Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/10387
CROSS-PROTECTIVE EFFECT OF A COMBINED L5 PLUS L3 LEISHMANIA MAJOR RIBOSOMAL PROTEIN BASED VACCINE COMBINED WITH A TH1 ADJUVANT IN MURINE CUTANEOUS AND VISCERAL LEISHMANIASIS.
L3 and L5 ribosomal proteins
BALB/c mice
Experimental infection
Vaccines
Leishmania major/imunologia
Vacinas contra Leishmaniose/imunologia
Leishmaniose Cutânea/prevenção & controle
Proteínas Ribossômicas/imunologia
Células Th1/imunologia
Animais
Citocinas/biossíntese
Feminino
Imunidade Celular
Imunidade Humoral
Leishmaniose Cutânea/imunologia
Leishmaniose Visceral/imunologia
Camundongos
Oligodesoxirribonucleotídeos
10.1186/1756-3305-7-3
Author
Affilliation
Universidad Autónoma de Madrid.Centro de Biología Molecular Severo Ochoa (CSIC-UAM). Departamento de Biología Molecular. Madrid, Spain
Universidad Autónoma de Madrid.Centro de Biología Molecular Severo Ochoa (CSIC-UAM). Departamento de Biología Molecular. Madrid, Spain
Universidade Federal de Minas Gerais. Faculdade de Medicina. Infectologia e Medicina Tropical. Belo Horizonte, MG, Brasil.
Universidade Federal de Minas Gerais. Faculdade de Medicina. Infectologia e Medicina Tropical. Belo Horizonte, MG, Brasil.
Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Bioquímica e Imunologia. Belo Horizonte, MG, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Research & Development Department, Laboratorios LETI. Madrid, Spain.
Universidad Autónoma de Madrid.Centro de Biología Molecular Severo Ochoa (CSIC-UAM). Departamento de Biología Molecular. Madrid, Spain
Universidad Autónoma de Madrid.Centro de Biología Molecular Severo Ochoa (CSIC-UAM). Departamento de Biología Molecular. Madrid, Spain
Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Bioquímica e Imunologia. Belo Horizonte, MG, Brasil
Universidade Federal de Minas Gerais. Faculdade de Medicina. Infectologia e Medicina Tropical. Belo Horizonte, MG, Brasil.
Universidad Autónoma de Madrid.Centro de Biología Molecular Severo Ochoa (CSIC-UAM). Departamento de Biología Molecular. Madrid, Spain
Universidad Autónoma de Madrid.Centro de Biología Molecular Severo Ochoa (CSIC-UAM). Departamento de Biología Molecular. Madrid, Spain
Universidade Federal de Minas Gerais. Faculdade de Medicina. Infectologia e Medicina Tropical. Belo Horizonte, MG, Brasil.
Universidade Federal de Minas Gerais. Faculdade de Medicina. Infectologia e Medicina Tropical. Belo Horizonte, MG, Brasil.
Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Bioquímica e Imunologia. Belo Horizonte, MG, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Research & Development Department, Laboratorios LETI. Madrid, Spain.
Universidad Autónoma de Madrid.Centro de Biología Molecular Severo Ochoa (CSIC-UAM). Departamento de Biología Molecular. Madrid, Spain
Universidad Autónoma de Madrid.Centro de Biología Molecular Severo Ochoa (CSIC-UAM). Departamento de Biología Molecular. Madrid, Spain
Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Bioquímica e Imunologia. Belo Horizonte, MG, Brasil
Universidade Federal de Minas Gerais. Faculdade de Medicina. Infectologia e Medicina Tropical. Belo Horizonte, MG, Brasil.
Universidad Autónoma de Madrid.Centro de Biología Molecular Severo Ochoa (CSIC-UAM). Departamento de Biología Molecular. Madrid, Spain
Abstract
BACKGROUND: Two Leishmania major ribosomal proteins L3 (LmL3) and L5 (LmL5) have been described as protective molecules against cutaneous leishmaniasis due to infection with L. major and Leishmania braziliensis in BALB/c mice when immunized with a Th1 adjuvant (non-methylated CpG-oligodeoxynucleotides; CpG-ODN). In the present study we analyzed the cross-protective efficacy of an LmL3-LmL5-CpG ODN combined vaccine against infection with Leishmania amazonensis and Leishmania chagasi (syn. Leishmania infantum) the etiologic agents of different clinical forms of human leishmaniasis in South America. METHODS: The combined vaccine was administered subcutaneously to BALB/c mice. After immunization the cellular and humoral responses elicited were analyzed. Mice were independently challenged with L. amazonensis and L. chagasi. The size of the cutaneous lesions caused by the infection with the first species, the parasite loads and the immune response in both infection models were analyzed nine weeks after challenge. RESULTS: Mice vaccinated with the combined vaccine showed a Th1-like response against LmL3 and LmL5. Vaccinated mice were able to delay lesion development due to L. amazonensis infection and to control parasite loads in the site of infection. A reduction of the parasite burden in the lymph nodes draining the site of infection and in the liver and spleen was observed in the vaccinated mice after a subcutaneous infection with L. chagasi. In both models of infection, protection was correlated to parasite antigen-specific production of IFN-γ and down-regulation of parasite-mediated IL-4 and IL-10 responses. CONCLUSIONS: The data presented here demonstrate the potential use of L. major L3 and L5 recombinant ribosomal proteins for the development of vaccines against various Leishmania species
Keywords
Leishmania parasitesL3 and L5 ribosomal proteins
BALB/c mice
Experimental infection
Vaccines
DeCS
Reações Cruzadas/imunologiaLeishmania major/imunologia
Vacinas contra Leishmaniose/imunologia
Leishmaniose Cutânea/prevenção & controle
Proteínas Ribossômicas/imunologia
Células Th1/imunologia
Animais
Citocinas/biossíntese
Feminino
Imunidade Celular
Imunidade Humoral
Leishmaniose Cutânea/imunologia
Leishmaniose Visceral/imunologia
Camundongos
Oligodesoxirribonucleotídeos
Publisher
BioMed Central
Citation
RAMIREZ, L. G. et al. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis. Parasites & Vectors, v. 7, p. 3, 2014.ISSN
1756-330510.1186/1756-3305-7-3
Share